AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05277844 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Consolidative Radiation Therapy
Description: Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
Study NCT05277844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI
Description: TKI
Study NCT02270502 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Philips CX50
Description: The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
Study NCT02270502 — intervention group
Intervention type: OTHER
Intervention: Frailty Index Questionnaire
Description: Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
Study NCT05277844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: TKI
Study NCT02270502 — intervention group
Intervention type: OTHER
Intervention: Muscle strength tests
Description: MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
Study NCT03775915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
Study NCT03775915 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Neurofeedback
Description: A visual representation of brain activity pre-recorded from a previous participant
Study NCT02152384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered SC
Study NCT02152384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT02152384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SC
Study NCT02152384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT00941447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
Study NCT00941447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
Study NCT00941447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulatory Approaches
Description: Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
Study NCT03043339 — intervention group
Intervention type: OTHER
Intervention: Stool Specimen Collection
Description: Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
Study NCT03043339 — intervention group
Intervention type: OTHER
Intervention: Anal Swab Sampling
Description: Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
Study NCT03043339 — intervention group
Intervention type: OTHER
Intervention: Short Diet Assessment (SDA)
Description: The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
Study NCT03043339 — intervention group
Intervention type: OTHER
Intervention: NHANES Dietary Screener Questionnaire (DSQ)
Description: The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
Study NCT03483714 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal Manipulation
Description: HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
Study NCT01330745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sublingual microcirculatory evaluation
Description: TNF, ICAM, syndecan-1, heparan sulfate
Study NCT04471805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation 4 mA
Description: Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
Study NCT04471805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation 4 mA
Description: Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
Study NCT04323514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 10 gr of vitamin C intravenously in addition to conventional therapy.
Study NCT03788707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive leg raising
Description: After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
Study NCT00783185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabis-Consumption-Reduction-Training
Description: 8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
Study NCT00783185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social competence Training
Description: 8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
Study NCT03848741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Exercise Control
Description: Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
Study NCT00395161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 0.2 mg/kg/dose IV every 12 hours
Study NCT00395161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients > 1 year of age)
Study NCT00395161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: one enteral dose daily of glutamine 0.3 gm/kg/day
Study NCT00395161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children > 13 years)
Study NCT00408408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2 IV
Study NCT00408408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV
Study NCT00395161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: equivalent volume of intravenous saline
Study NCT02293070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed Enhanced Cardiac Magnetic Resonance Imaging
Description: Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
Study NCT02293070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
Study NCT01525147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: Level 2
Description: IV infusion
Study NCT01525147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: Level 3
Description: IV infusion
Study NCT01525147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: Level 4
Description: IV infusion
Study NCT01525147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: Level 5
Description: IV infusion
Study NCT01525147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion
Study NCT00395161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: equivalent volume of sterile water
Study NCT00395161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: selenium
Description: equivalent volume of sterile water
Study NCT00395161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey-protein
Description: one enteral dose daily of whey-protein
Study NCT02899962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam
Description: LEO 90100 aerosol foam twice weekly
Study NCT02899962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 aerosol foam vehicle
Description: LEO 90100 aerosol foam vehicle twice weekly
Study NCT03180281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP4
Description: sitagliptin phosphate 100mg qd
Study NCT03180281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin Glargine or detemir 0.2U/kg qd
Study NCT03180281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SU
Description: Glimepiride 1-2mg qd
Study NCT06499675 — intervention group
Intervention type: PROCEDURE
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy / bariatric surgery
Study NCT06499675 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: intraoperative liver biopsy
Study NCT01938495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuRx® Diaphragm Pacing System™ (DPS)
Description: The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
Study NCT01613768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT03142191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 is a potent, selective inhibitor of JNK.
Study NCT03142191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02017015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
Study NCT02017015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
Study NCT01023035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg given three times a day (TID), orally (PO)
Study NCT01023035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PEG2b)
Description: 1.5 µg/kg/week given subcutaneously (SC)
Study NCT01023035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
Study NCT01023035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
Study NCT03672227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime Matters Training
Description: This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
Study NCT03324295 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cortical cataract
Description: Blood urea
Study NCT04590105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone App SB Colonoscopy Prep
Description: We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
Study NCT04590105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Instruction
Description: Written Instruction
Study NCT00953966 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Genetically modified potatoes
Description: Starch from genetically modified potatoes
Study NCT02647697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil oral
Description: * Active Substance: Radiprodil~* Pharmaceutical Form: dry granules for oral suspension~* Concentration: 30 mg~* Route of Administration: oral use
Study NCT03832205 — intervention group
Intervention type: DEVICE
Intervention: Capaciflector monitoring
Description: Non-invasive capaciflector monitoring of respiratory rate and heart rate.
Study NCT03390803 — intervention group
Intervention type: OTHER
Intervention: effect of hemifacial spasm on intraocular pressure
Description: To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
Study NCT01525147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YHB1411-2: level 1
Description: IV infusion
Study NCT01526889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Description: LFG316 administered intravitreally (IVT)
Study NCT01526889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional Therapy administered in accordance with its prescribing info.
Study NCT00408408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 100 mg/m2 IV
Study NCT00408408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg/m2 IV
Study NCT00408408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride (Adriamycin)
Description: 60 mg/m2 IV
Study NCT00408408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride (Adriamycin)
Description: 60 mg/m2 IV
Study NCT00408408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV
Study NCT02718131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INFUSE Bone Graft (BMP-2)
Description: The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
Study NCT02718131 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will receive the standard surgical protocol, without addition of the INFUSE device.
Study NCT01028859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-516 inj
Description: 5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks
Study NCT02108158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azzalure
Study NCT02108158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azzalure
Study NCT04235959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT04235959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00608426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Outreach with choice of telephone or in-person smoking cessation services
Description: This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
Study NCT01613209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
Study NCT01613209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipin
Description: olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
Study NCT02463812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Study NCT02463812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00706420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Transplantation + Immunosuppression
Description: Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)
Study NCT00706420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Description: Islet cell transplantation will occur through the portal vein.
Study NCT03898297 — intervention group
Intervention type: RADIATION
Intervention: [18F]FPEB
Description: Radiotracer: \[18F\]FPEB
Study NCT01408459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No Motivational telephone Counseling
Study NCT04085913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Epinephrine
Description: Preincision injection, as is current practice
Study NCT04085913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride-EPINEPHrine
Description: Preincision injection
Study NCT04085913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
Description: Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
Study NCT00601549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Laparoscopic surgery
Study NCT00601549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional open surgery
Description: Open surgery
Study NCT03898297 — intervention group
Intervention type: RADIATION
Intervention: [11C]APP311
Description: Radiotracer: \[11C\]APP311, \[11C\]UCB-J
Study NCT03848741 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Exercise Control
Description: Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
Study NCT03848741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Participants will complete a 12-week whole-body progressive resistance exercise training program.
Study NCT03848741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise Training
Description: Participants will complete a 12-week whole-body progressive resistance exercise training program.
Study NCT03848741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given placebo capsules to consume for 12-weeks.
Study NCT03848741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will be given placebo capsules to consume for 12-weeks.
Study NCT00963742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lenstec Softec HD IOL implantation
Description: surgical removal of cataract and implantation of Softec HD PCIOL